Insider and congress filings
Biogen Inc. (BIIB)
About Biogen Inc.
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Chief executive
- Christopher A. Viehbacher
- Employees
- 7,500
- Listed since
- Sep 17, 1991
- Market value
- $31.1B
- Price to earnings
- 37.1
- Earnings per share
- $5.65
- Dividend yield
- -
Earnings
6 reported quarters · next on Oct 29, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Jul 29, 2026 | $3.60 | $2.94 | $2.7B | $2.5B | EPS beatRevenue beat |
| Q1 FY2026reported Apr 29, 2026 | $3.57 | $3.05 | $2.5B | $2.3B | EPS beatRevenue beat |
| Q4 FY2025reported Feb 6, 2026 | $1.99 | $1.63 | $2.3B | $2.2B | EPS beatRevenue beat |
| Q3 FY2025reported Oct 30, 2025 | $4.81 | $3.88 | $2.5B | $2.3B | EPS beatRevenue beat |
| Q2 FY2025reported Jul 31, 2025 | $5.47 | $3.90 | $2.6B | $2.3B | EPS beatRevenue beat |
| Q1 FY2025reported May 1, 2025 | $3.02 | $2.90 | $2.4B | $2.2B | EPS beatRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 28, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Christopher A. ViehbacherPresident and Chief Executive Officer | $1.7M | $18.4M | $3.5M | $23.6M |
| Susan H. AlexanderExecutive Vice President, Chief Legal Officer | $1.0M | $5.8M | $1.3M | $8.1M |
| Nicole C.Murphy Head of Pharmaceutical Operations and Technolog | $909K | $5.6M | $1.1M | $7.6M |
| Priya A.Singhal Head of Development | $930K | $5.6M | $1.1M | $7.6M |
| Robin C. KramerExecutive Vice President and Chief Financial Officer | $760K | $4.2M | $873K | $5.8M |
The summary compensation table from the 2025 proxy statement, current executives only. 1 executive who has since left the company is named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| FMR LLC | $3.9B | 18,217,239 | +42.2% | 12.33% |
| Blackrock, Inc. | $3.5B | 15,985,736 | +0.1% | 10.82% |
| Primecap Management Co | $3.3B | 15,154,606 | +2.7% | 10.26% |
| Vanguard Capital Management LLC | $2.1B | 9,651,117 | +1.2% | 6.53% |
| State Street Corp | $1.6B | 7,344,327 | +2.5% | 4.97% |
| Vanguard Portfolio Management LLC | $1.4B | 6,604,936 | +1.1% | 4.47% |
| Geode Capital Management, LLC | $957.9M | 4,449,295 | +2.5% | 3.01% |
| Wellington Management Group LLP | $673.6M | 3,117,469 | +5.3% | 2.11% |
| Norges Bank | $557.4M | 2,580,033 | +100.0% | 1.75% |
| Morgan Stanley | $521.0M | 2,411,271 | +11.1% | 1.63% |
| AQR Capital Management LLC | $416.9M | 1,936,859 | +0.7% | 1.31% |
| Jpmorgan Chase & Co | $394.9M | 1,823,140 | -9.6% | 1.23% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Open-market insider trades
4 filings of 294 on record| Insider | Action | Shares | Price | Value | Trade date | Delay |
|---|---|---|---|---|---|---|
| Lloyd MinorDirector | Sold | 593 | $203.34 | $121K | Aug 3, 2026 | 2d |
| Lloyd MinorDirector | Sold | 593 | $200.96 | $119K | Aug 4, 2026 | 1d |
| Nicole MurphyHead of Pharm Ops and Tech | Bought | 3 | $195.03 | $585 | Feb 12, 2026 | 5d |
| Priya SinghalHead of Development | Sold | 2,660 | $199.83 | $532K | Feb 9, 2026 | 1d |
One row is one filing. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count.
Congress trades in BIIB
20 disclosures of 125 on record · median 27d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Kevin Hern | Stock | Sale | $1,001 - $15,000 | -0.9%S&P -0.6% · vs S&P 500 -0.2% | Aug 18, 2026 | Sep 1, 2026 | 14d |
| Alan ArmstrongSelfFiled late | Stock | Purchase | $1,001 - $15,000 | +14.6%S&P +20.2% · vs S&P 500 -5.6% | Mar 27, 2026 | Jul 21, 2026 | 116d |
| Maria Elvira Salazar | Stock | Sale | $15,001 - $50,000 | +11.6%S&P +0.4% · vs S&P 500 +11.2% | Jun 2, 2026 | Jul 7, 2026 | 35d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +7.9%S&P +3.4% · vs S&P 500 +4.5% | Jun 5, 2026 | Jul 2, 2026 | 27d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +7.0%S&P +1.6% · vs S&P 500 +5.4% | May 27, 2026 | Jun 9, 2026 | 13d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +9.2%S&P +3.2% · vs S&P 500 +6.1% | May 15, 2026 | Jun 9, 2026 | 25d |
| Maria Elvira Salazar | Stock | Purchase | $1,001 - $15,000 | +6.5%S&P +3.1% · vs S&P 500 +3.3% | May 11, 2026 | Jun 8, 2026 | 28d |
| Maria Elvira Salazar | Stock | Purchase | $50,001 - $100,000 | +6.5%S&P +3.1% · vs S&P 500 +3.3% | May 11, 2026 | Jun 8, 2026 | 28d |
| Maria Elvira Salazar | Stock | Purchase | $1,001 - $15,000 | +5.7%S&P +3.3% · vs S&P 500 +2.4% | May 12, 2026 | Jun 8, 2026 | 27d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +19.5%S&P +11.1% · vs S&P 500 +8.4% | Apr 13, 2026 | May 11, 2026 | 28d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +4.8%S&P +10.3% · vs S&P 500 -5.6% | Feb 6, 2026 | Mar 9, 2026 | 31d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +17.1%S&P +10.2% · vs S&P 500 +7.0% | Jan 30, 2026 | Feb 13, 2026 | 14d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +19.6%S&P +9.8% · vs S&P 500 +9.8% | Jan 29, 2026 | Feb 6, 2026 | 8d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +54.1%S&P +18.2% · vs S&P 500 +36.0% | Aug 26, 2025 | Sep 9, 2025 | 14d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +62.8%S&P +28.2% · vs S&P 500 +34.6% | May 19, 2025 | Jun 10, 2025 | 22d |
| Robert Bresnahan | Stock | Purchase | $1,001 - $15,000 | +70.4%S&P +29.1% · vs S&P 500 +41.2% | May 15, 2025 | Jun 9, 2025 | 25d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +78.3%S&P +42.4% · vs S&P 500 +35.9% | Apr 23, 2025 | May 12, 2025 | 19d |
| Robert Bresnahan | Stock | Sale | $1,001 - $15,000 | +84.8%S&P +53.5% · vs S&P 500 +31.3% | Apr 8, 2025 | May 8, 2025 | 30d |
| Robert Bresnahan | Stock | Purchase | $1,001 - $15,000 | +46.9%S&P +28.3% · vs S&P 500 +18.6% | Feb 25, 2025 | Mar 27, 2025 | 30d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +46.9%S&P +28.3% · vs S&P 500 +18.6% | Feb 25, 2025 | Mar 6, 2025 | 9d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Members of Congress reporting a position
5 members · estimate, as of Sep 10, 20265 members report a position (estimated). The largest estimated position is in the $50,001 - $100,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| J. French Hill | Republican · House | $50,001 - $100,000 | 0.5% |
| Maria Elvira Salazar | Republican · House | $50,001 - $100,000 | 2.6% |
| Gilbert Ray Cisneros, Jr. | Democrat · House | $15,001 - $50,000 | 0.1% |
| Robert Bresnahan | Republican · House | $1,001 - $15,000 | 0.1% |
| Kevin Hern | Republican · House | $1,001 - $15,000 | <0.1% |
Estimate, as of Sep 10, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Awards, option exercises and gifts (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Michael PariniChief Legal Officer | Stock award | 7,405 | Sep 1, 2026 |
| Eric K. RowinskyDirector | Stock award | 1,505 | Jun 9, 2026 |
| Maria C. FreireDirector | Stock award | 2,005 | Jun 9, 2026 |
| Lloyd MinorDirector | Stock award | 1,505 | Jun 9, 2026 |
| Menelas N. PangalosDirector | Option exercise | 2,370 | Jun 9, 2026 |
| Menelas N. PangalosDirector | Stock award | 1,505 | Jun 9, 2026 |
| Monish D. PatolawalaDirector | Stock award | 1,505 | Jun 9, 2026 |
| Susan LangerDirector | Stock award | 1,505 | Jun 9, 2026 |
| Jesus B. MantasDirector | Stock award | 1,505 | Jun 9, 2026 |
| Stephen A. SherwinDirector | Stock award | 1,505 | Jun 9, 2026 |
| William A. HawkinsDirector | Stock award | 1,505 | Jun 9, 2026 |
| Adam KeeneyHead of Corporate Development | Tax withholding | 455 | May 1, 2026 |
| Adam KeeneyHead of Corporate Development | Option exercise | 939 | May 1, 2026 |
| Sean GodboutChief Accounting Officer | Tax withholding | 54 | Apr 1, 2026 |
| Sean GodboutChief Accounting Officer | Option exercise | 181 | Apr 1, 2026 |
| Sean GodboutChief Accounting Officer | Stock award | 1,800 | Feb 13, 2026 |
| Susan H. AlexanderEVP Chief Legal Officer | Stock award | 8,450 | Feb 13, 2026 |
| Christopher ViehbacherPresident and CEO | Stock award | 38,015 | Feb 13, 2026 |
| Priya SinghalHead of Development | Stock award | 10,560 | Feb 13, 2026 |
| Nicole MurphyHead of Pharm Ops and Tech | Stock award | 10,560 | Feb 13, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Questions
Are insiders buying or selling BIIB?
Across the 4 most recent open-market filings shown here, 1 was a purchase and 3 were sales.
Which members of Congress have traded BIIB?
Kevin Hern, Alan Armstrong, Maria Elvira Salazar, Gilbert Ray Cisneros, Jr., Ro Khanna, Robert Bresnahan disclosed BIIB transactions in the filings shown here.
Which members of Congress hold BIIB?
5 members of Congress report a position in BIIB in the estimate we hold as of Sep 10, 2026. The three largest estimated positions belong to J. French Hill, Maria Elvira Salazar and Gilbert Ray Cisneros, Jr.. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Is BIIB in the S&P 500 or the Nasdaq 100?
Biogen Inc. is a current member of the S&P 500, per the membership list we hold as of Sep 10, 2026. Current members of either index get a page here whatever their filing history.
How quickly are BIIB trades disclosed?
Insider filings on this page reached the public a median of 2 days after the transaction, against the two business days Form 4 allows. Congressional disclosures took a median of 27 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.